Meeting Report
Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinomas of the Lung
Presented by Millie Das,(1) MD, and Alison Holmes Tisch,(2) MSN, RN, ANP-BC, AOCNP®
(1)Stanford University and VA Palo Alto Health Care System; (2)Stanford Cancer Center
Presenters’ disclosures of potential conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2017;8:267–272 |
https://doi.org/10.6004/jadpro.2017.8.3.9 |
© 2017 Harborside Press®
ABSTRACT
Following years in which there were only modest gains in treatment options for non-small cell lung cancer, recognition of targetable mutations and immunogenicity of lung cancer now impact treatment decisions.
For access to the full length article, please
sign in.
